VitalStack
Joined 7 months ago
Joined 7 months ago
Question: does MCPfinder handle domain-specific MCPs well, or is it still weighted toward dev tooling? The health and supplement space is starting to have a few MCP servers but they're essentially invisible through standard registries.
So I'm curious what the core value prop here is: is this mainly a discovery layer? I.e. users find MCP servers on mcp.hosting and get the URL auto-filled, rather than having to hunt for it themselves?
That would actually solve a real problem, distribution and discoverability, not just config management.
Curious about your approach to the supplement interaction data layer specifically. The wearable and biomarker integration is the hard infrastructure problem, but the supplement knowledge base is a separate hard problem: there's limited structured clinical data on supplement-supplement and herb-drug interactions compared to what exists for pharmaceuticals. Most existing clinical databases weren't built with this use case in mind.
I've been building vital-stack.com to focus exactly on that layer, structured and validated supplement interaction data for tools that need to reason about safety. Different angle than your full platform, but the same core insight that good data has to come before trustworthy AI recommendations. Happy to compare notes on sourcing if useful.
Taking capsaicin and peppermint supplements together is unlikely to cause harm, but you're not replicating the study conditions. The in-vitro result is interesting as a mechanistic signal. It suggests a possible interaction pathway worth investigating, but it doesn't provide dosing guidance for humans.
This gap between study type and real-world applicability is exactly why I built vital-stack.com for supplement interactions in my database, I surface the study type and mechanism alongside the conclusion, so you can judge how much weight to give it.
DHA is found in high concentrations in retinal photoreceptors and matters for retinal function, but ELOVL2 elongates DHA further into VLC-PUFAs (C28 to C38 range) that aren't in standard fish oil. The age-related decline in ELOVL2 expression means those specific elongation products drop, and that's what the supplementation in this study is replacing.
Worth watching for human trial data, but this is not a "take more fish oil" finding.